Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ERN1 | O75460 | 3/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | GPR142 | Q7Z601 | 7/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15749928 | 0.81 | DYRK1A (0.60) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL21882390 | 0.80 | CYP11B1 (0.69) | DYRK1ARAB9AERN1NPC1 | |
| SCHEMBL27310561 | 0.80 | DYRK1A (0.58) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL19188073 | 0.80 | DYRK1A (0.58) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL27310562 | 0.80 | MAPT (0.64) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL17165448 | 0.80 | DYRK1A (0.45) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL3135370 | 0.79 | DYRK1A (0.57) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL18609187 | 0.78 | PIK3CA (0.49) | DYRK1ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL21317942 | 0.78 | DYRK1A (0.43) | DYRK1ARAB9AMAPTSMN1; SMN2ERN1 | |
| SCHEMBL15071791 | 0.78 | MAPK14 (0.49) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | DYRK1A 4734/4885RAB9A 1535/4885MAPT 1608/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | DYRK1A 4734/4885RAB9A 1535/4885MAPT 1608/4885 |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | DYRK1A 4734/4885RAB9A 1535/4885MAPT 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.